A citation-based method for searching scientific literature

Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
Times Cited: 5







List of co-cited articles
14 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
60

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
60

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
60

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
75
40

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
Judith van Dalem, Martijn C G J Brouwers, Coen D A Stehouwer, André Krings, Hubert G M Leufkens, Johanna H M Driessen, Frank de Vries, Andrea M Burden. BMJ 2016
39
40

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
40

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
40

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
40

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Lindsay E Clegg, Hiddo J L Heerspink, Robert C Penland, Weifeng Tang, David W Boulton, Srinivas Bachina, Robert D Fox, Peter Fenici, Marcus Thuresson, Robert J Mentz,[...]. Diabetes Care 2019
17
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson,[...]. Eur Heart J 2020
51
40

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40


Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.
Nils Ekström, Linus Schiöler, Ann-Marie Svensson, Katarina Eeg-Olofsson, Junmei Miao Jonasson, Björn Zethelius, Jan Cederholm, Björn Eliasson, Soffia Gudbjörnsdottir. BMJ Open 2012
145
20

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
227
20

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
H C Gerstein, J F Mann, Q Yi, B Zinman, S F Dinneen, B Hoogwerf, J P Hallé, J Young, A Rashkow, C Joyce,[...]. JAMA 2001
20

Metformin initiation and renal impairment: a cohort study in Denmark and the UK.
Christian Fynbo Christiansen, Vera Ehrenstein, Uffe Heide-Jørgensen, Stine Skovbo, Helene Nørrelund, Henrik Toft Sørensen, Lin Li, Susan Jick. BMJ Open 2015
4
25

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Sophia Zoungas, Hisatomi Arima, Hertzel C Gerstein, Rury R Holman, Mark Woodward, Peter Reaven, Rodney A Hayward, Timothy Craven, Ruth L Coleman, John Chalmers. Lancet Diabetes Endocrinol 2017
175
20

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
416
20

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
55
20

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
440
20

Hypoglycemia in Patients with Diabetes and Renal Disease.
Mazen Alsahli, John E Gerich. J Clin Med 2015
49
20

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
David M Williams, Asif Nawaz, Marc Evans. Diabetes Ther 2020
24
20


Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
Young-Gun Kim, JungHyun Byun, Dukyong Yoon, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Kwan-Woo Lee, Rae Woong Park, Hae Jin Kim. J Diabetes Res 2016
21
20

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Marcel H A Muskiet, Lennart Tonneijck, Yao Huang, Minzhi Liu, Aramesh Saremi, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2018
71
20


Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
231
20

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Girish N Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E Grams, Steven G Coca. Diabetes Care 2017
72
20

Diabetic nephropathy: diagnosis, prevention, and treatment.
Jorge L Gross, Mirela J de Azevedo, Sandra P Silveiro, Luís Henrique Canani, Maria Luiza Caramori, Themis Zelmanovitz. Diabetes Care 2005
874
20

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.
Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber. J Diabetes Investig 2019
29
20

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger,[...]. Am J Nephrol 2014
76
20

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque,[...]. Nephrol Dial Transplant 2019
70
20

Metformin-Associated Lactic Acidosis Undergoing Renal Replacement Therapy in Intensive Care Units: A Five-Million Population-Based Study in the North-West of Italy.
Filippo Mariano, Marco Pozzato, Paola Inguaggiato, Cesare Guarena, Ernesto Turello, Massimo Manes, Paola David, Silvia Berutti, Valentina Consiglio, Alessandro Amore,[...]. Blood Purif 2017
13
20

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
32
20

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
812
20

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Paola Fioretto, Bergur V Stefansson, Eva Johnsson, Valerie A Cain, C David Sjöström. Diabetologia 2016
54
20

Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease.
Wei-Hao Hsu, Pi-Jung Hsiao, Pi-Chen Lin, Szu-Chia Chen, Mei-Yueh Lee, Shyi-Jang Shin. Oncotarget 2017
16
20

Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes.
Julie A Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, Leif E Lovblom, Shajiha Khan, Robel Alemu, Amy Locke, Vesta Lai, Huaibing He, Lucinda Hittle,[...]. Diabetes Care 2017
63
20

Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality.
Ki-Chul Sung, Seungho Ryu, Jong-Young Lee, Sung Ho Lee, EunSun Cheong, Young-Youl Hyun, Kyu-Beck Lee, Hyang Kim, Christopher D Byrne. J Am Heart Assoc 2016
37
20


Standards of medical care in diabetes.
David Power. Diabetes Care 2006
16
20

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Russell Scott, Jerry Morgan, Zachary Zimmer, Raymond L H Lam, Edward A O'Neill, Keith D Kaufman, Samuel S Engel, Annaswamy Raji. Diabetes Obes Metab 2018
14
20

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J Xu, Shrita Patel, Anne Hickman, James P Mancuso,[...]. Diabetologia 2020
12
20

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
20

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Jan H Cornel, George L Bakris, Susanna R Stevens, Michael Alvarsson, Willem A Bax, Lee-Ming Chuang, Samuel S Engel, Renato D Lopes, Darren K McGuire, Axel Riefflin,[...]. Diabetes Care 2016
90
20

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
95
20


Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.
Giuseppe Coppolino, Christian Leporini, Laura Rivoli, Francesco Ursini, Eugenio Donato di Paola, Valeria Cernaro, Franco Arturi, Davide Bolignano, Emilio Russo, Giovambattista De Sarro,[...]. Pharmacol Res 2018
26
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.